Everolimus, a synthetic analogue of rapamycin, is an mTOR inhibitor (mTORi) approved by the EMA as Votubia (EMA/229443/2018) as an adjunctive treatment in patients from 2 years of age with partial-onset seizures related to TSC that have not responded to other treatments, and for the treatment of SEGAs and AMLs. This evidence concerns the gene MTOR and tuberous sclerosis.